Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

BRC.4 -- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib -- was activated on 14 May 2009.
http://www.ctg.queensu.ca/trials/lung/brc4/brc4.html